Bepranemab (UCB0107) | UCB
UCB's Global Corporate Website

Bepranemab (UCB0107)

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) Phase 2 AH0003
Ongoing
NCT04867616
2020-005829-88
Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Phase 1 PSP002
Ongoing
NCT04658199